ATXN1L

ATXN1L functions as an essential stabilizer and cofactor of the transcriptional repressor CIC, forming a complex that suppresses ETS family transcription factors (ETV1/ETV4/ETV5), Notch target genes, and interferon/interferon-stimulated gene promoters. ATXN1L binding protects CIC from TRIM25-mediated polyubiquitination and proteasomal degradation; loss of ATXN1L destabilizes CIC, de-repressing downstream targets including MMPs, cell-cycle genes, and IFN/ISG loci, thereby modulating MAPK pathway sensitivity, extracellular matrix remodeling, hematopoietic stem cell quiescence, marginal zone B cell development, and antiviral innate immunity (PMID:22014525, PMID:33115448, PMID:28178529, PMID:39632849, PMID:40132591). ATXN1L competes with its paralog ATXN1 for incorporation into the CIC complex, and elevated ATXN1L displaces polyglutamine-expanded ATXN1, suppressing spinocerebellar ataxia type 1 (SCA1) neuropathology in mice (PMID:17322884). During viral infection, MAPK activation triggers rapid degradation of the CIC–ATXN1L complex, relieving repression of an 8-nucleotide motif at IFN/ISG promoters and enabling innate immune gene induction (PMID:40132591).

1. 2007 High

   Whether ATXN1L participates in the same complex as ATXN1 was unknown; demonstrating that ATXN1L competes with mutant ATXN1 for the native CIC-containing complex established it as a functional paralog and potential modifier of SCA1 disease.

   Evidence Targeted duplication of mouse Atxn1l locus plus co-immunoprecipitation in SCA1 knock-in mice showing displacement of mutant ATXN1

   PMID:17322884

   Open questions at the time

   • Structural basis for competitive binding not determined
   • Whether ATXN1L and ATXN1 have non-overlapping functions beyond CIC complex occupancy was unclear
2. 2011 High

   The molecular consequence of ATXN1L loss was unknown; knockout studies revealed that ATXN1L stabilizes CIC protein and that its absence de-represses ETV4/MMP targets causing lung alveolarization defects, establishing the ATXN1L–CIC–ETS axis as a physiological regulatory module.

   Evidence Atxn1L single and Atxn1/Atxn1L double knockout mice with gene expression and developmental phenotyping; ChIP and co-IP showing ATXN1L binding at Notch target (Hey1) promoters with CBF1

   PMID:21475249 PMID:22014525

   Open questions at the time

   • Mechanism by which ATXN1L stabilizes CIC protein was not identified
   • Whether Notch regulation via CBF1 is CIC-dependent or represents an independent ATXN1L function was unresolved
3. 2013 Medium

   Whether ATXN1L regulates stem cell biology was untested; Atxn1L-null mice showed expanded, hyperproliferative HSCs, linking the CIC-stabilizing function to maintenance of hematopoietic stem cell quiescence.

   Evidence Atxn1L knockout mice with in vivo and in vitro HSC assays and molecular profiling

   PMID:23555280

   Open questions at the time

   • Whether HSC phenotype is CIC-dependent was not formally tested with epistasis
   • Downstream gene programs driving quiescence loss were not fully defined
4. 2017 High

   Whether the ATXN1L–CIC axis has therapeutic relevance was unknown; genome-scale CRISPR screens identified ATXN1L loss as a driver of resistance to MEK/RAF inhibitors through de-repression of ETV1/4/5, connecting this complex to MAPK pathway drug sensitivity in cancer.

   Evidence Genome-scale CRISPR-Cas9 screens in cancer cell lines; ectopic ETV expression phenocopying ATXN1L loss

   PMID:28178529

   Open questions at the time

   • Whether restoring ATXN1L or CIC can re-sensitize resistant tumors was not tested
   • Relative contribution of individual ETV factors to resistance was not resolved
5. 2020 High

   The biochemical mechanism by which CIC is destabilized upon ATXN1L loss was unknown; identification of TRIM25 as the E3 ligase that polyubiquitinates CIC for proteasomal degradation — independently of ERK activity — provided the missing proteolytic link.

   Evidence ATXN1L-KO human cell lines with proteasome inhibitor treatment, ubiquitination assays, and TRIM25 knockdown/overexpression across multiple cell systems

   PMID:33115448

   Open questions at the time

   • How ATXN1L physically shields CIC from TRIM25 access is unknown
   • Whether additional E3 ligases contribute in other tissues was not explored
6. 2024 High

   Whether the ATXN1L–CIC–ETV4 axis operates in immune cell development was untested; conditional B cell-specific knockout demonstrated that ATXN1L deficiency de-represses ETV4, which in turn suppresses Notch1/2 transcription and impairs marginal zone B cell differentiation.

   Evidence B cell-specific Atxn1l conditional KO mice (Atxn1l-fl/fl;Cd19-Cre) with Etv4-deletion epistasis rescue and flow cytometry

   PMID:39632849

   Open questions at the time

   • Whether other B cell subsets or T cell development are affected was not fully characterized
   • Whether this mechanism contributes to immunodeficiency phenotypes in humans is unknown
7. 2025 High

   Whether the CIC–ATXN1L complex directly controls innate immune gene expression was unknown; identification of an 8-nucleotide binding motif at IFN/ISG promoters and demonstration that MAPK-triggered complex degradation during viral infection relieves this repression established a direct transcriptional switch for antiviral immunity.

   Evidence DNA-binding assays, CIC/ATXN1L CRISPR-KO in human and mouse cells, ChIP at IFN/ISG promoters, and viral infection models with MAPK activation

   PMID:40132591

   Open questions at the time

   • Whether CIC–ATXN1L degradation kinetics differ by virus type is unknown
   • The relative contribution of ATXN1L loss versus CIC phosphorylation to complex dissolution is not separated

• The structural basis for how ATXN1L shields CIC from TRIM25-mediated ubiquitination, the determinants of isoform-selective CIC-S/ATXN1L versus CIC-L/ATXN1 pairing, and the full spectrum of tissue-specific CIC–ATXN1L target genes remain to be determined.
• No structural model of the ATXN1L–CIC interface exists
• Isoform-specific pairing determinants identified only in preprint
• Genome-wide direct binding targets across tissues are not comprehensively mapped